SL-401

Phase 1Small molecule

SL-401 is one of 18 small molecule programs targeting Blastic Plasmacytoid Dendritic Cell Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Blastic Plasmacytoid Dendritic Cell NeoplasmActive, not recruiting

Blastic Plasmacytoid Dendritic Cell NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Blastic Plasmacytoid Dendritic Cell Neoplasm

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 2

3 2

Rituxan

Roche

Phase 2

1 3

Adriamycin

Pfizer

Phase 2

1 4

Trexall

Alnylam Pharmaceuticals

Phase 2

1 5

Oncovin

Eli Lilly

Phase 2

1 6

Cytosar

Teva

Phase 2

1 7

Medrol

Pfizer

Phase 2

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 9

Purinethol

SStason

Phase 2

1 10

Decadron

AAspen Global Incorporated

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT03113643

Clinical

Trials by Indication[1]

Blastic Plasmacytoid Dendritic Cell Neoplasm1 trial

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Recruiting·—·Phase 1·NCT03113643·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SL-401. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SL-401 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SL-401. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dana-Farber Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDana-Farber Cancer Institute

SL-401

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Blastic Plasmacytoid Dendritic Cell Neoplasm1 trial

References

Drug Info

Quick Facts

Related News